To assess the effectiveness and safety of osimertinib treatment in a real world setting.
Name: osimertinib
Description: Overall response rate (ORR), defined as the proportion of patients with a best response of "responding" to treatment by investigator assessment
Measure: ORR Time: Followed up with 6 months after last patient inDescription: Progression free survival (PFS), defined as the time from the date of first dose of osimertinib to the date of investigator-assessed disease progression or death from any cause during study. Subjects who have not progressed or died at the time of analysis will be censored at the time of the latest date of assessment
Measure: PFS Time: Followed up 10 months after last subject inDescription: Average turnaround time.
Measure: T790M mutation testing time Time: Within 14 days after enrollment dateDescription: To assess by number of previous adopted/current/future therapies as recorded on the case report form
Measure: Treatment patterns Time: Followed up 10 months after last patient inDescription: To assess by number of adverse events as recorded on the case report form.
Measure: Adverse events Time: Follow up 10 months after last patient in.Description: To assess by intensity of adverse events as recorded on the case report form, which will be measured by CTCAE grade system
Measure: Adverse event intensity Time: Follow up 10 months after last patient in.Description: To assess by proportion of testing samples types as recorded on the case report form.
Measure: T790M mutation testing sample Time: Within 14 days after enrollment dateDescription: To assess by proportion of each testing platform as recorded on the case report form.
Measure: T790M mutation testing platform Time: Within 14 days after enrollment dateDescription: To assess by proportion of EGFR mutation subtype as recorded on the case report form
Measure: EGFR testing mutation subtype Time: Within 14 days after enrollment dateCohort
There is one SNP
An Observational, Retrospective, Real World Study of Osimertinib in Ethnic Chinese Patients With Locally Advanced/Metastatic T790M Mutation-Positive Non-small-cell Lung Cancer (NSCLC )Progressed on Previous Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI).. Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC To assess the effectiveness and safety of osimertinib treatment in a real world setting. --- T790M ---
An Observational, Retrospective, Real World Study of Osimertinib in Ethnic Chinese Patients With Locally Advanced/Metastatic T790M Mutation-Positive Non-small-cell Lung Cancer (NSCLC )Progressed on Previous Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI).. Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC To assess the effectiveness and safety of osimertinib treatment in a real world setting. --- T790M --- --- T790M ---
T790M mutation testing time. --- T790M ---
T790M mutation testing sample. --- T790M ---
To assess by proportion of testing samples types as recorded on the case report form.. T790M mutation testing platform. --- T790M ---
Inclusion Criteria: - Above 18 years of age; - Locally advanced (stage IIIB) or metastatic (stage IV) NSCLC, not amenable to curative surgery or radiotherapy - Confirmed T790M mutation - Progressed on previous EGFR TKI treatment. --- T790M ---
Patients may have also received additional lines of treatment - Received osimertinib treatment in the participating site between May 1st and Oct 31st 2016 Exclusion Criteria: • Enrolment in studies that prohibit any participation in this observational study Inclusion Criteria: - Above 18 years of age; - Locally advanced (stage IIIB) or metastatic (stage IV) NSCLC, not amenable to curative surgery or radiotherapy - Confirmed T790M mutation - Progressed on previous EGFR TKI treatment. --- T790M ---
Patients may have also received additional lines of treatment - Received osimertinib treatment in the participating site between May 1st and Oct 31st 2016 Exclusion Criteria: • Enrolment in studies that prohibit any participation in this observational study T790M Positive NSCLC Patients Carcinoma, Non-Small-Cell Lung The current study will not only assess the effectiveness of osimertinib treatment in a real world setting, but will also help us to understand the real-world testing patterns among T790M mutation positive locally advanced or metastatic NSCLC patients who have progressed after EGFR TKI treatment. --- T790M ---
Patients may have also received additional lines of treatment - Received osimertinib treatment in the participating site between May 1st and Oct 31st 2016 Exclusion Criteria: • Enrolment in studies that prohibit any participation in this observational study T790M Positive NSCLC Patients Carcinoma, Non-Small-Cell Lung The current study will not only assess the effectiveness of osimertinib treatment in a real world setting, but will also help us to understand the real-world testing patterns among T790M mutation positive locally advanced or metastatic NSCLC patients who have progressed after EGFR TKI treatment. --- T790M --- --- T790M ---